Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans

Drug Metabolism and Disposition

Volumn 44, Issue 8, 2016, Pages 1148-1157

  Shen, Jianwei ^a   Serby, Michael ^a   Surber, Bruce ^a   Lee, Anthony J ^a   Ma, Junli ^a   Badri, Prajakta ^a   Menon, Rajeev ^a   Kavetskaia, Olga ^a,b   De Morais, Sonia M ^a   Sydor, Jens ^a   Fischer, Volker ^a  

^a ABBVIE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTIVIRUS AGENT; CARBON 14; CYTOCHROME P450 2C8; DASABUVIR; DRUG METABOLITE; OMBITASVIR; PARITAPREVIR PLUS RITONAVIR; UNCLASSIFIED DRUG; ABT-267; ANILIDE; CARBAMIC ACID DERIVATIVE; CYP2C8 PROTEIN, HUMAN; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS BALANCE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PHYSICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BLOOD; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; FECES; HEPACIVIRUS; HYDROLYSIS; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANILIDES; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2C8; DRUG ADMINISTRATION SCHEDULE; FECES; HEALTHY VOLUNTEERS; HEPACIVIRUS; HUMANS; HYDROLYSIS; MALE; OXIDATION-REDUCTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84978066079     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067496     Document Type: Article

References (23)

1. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, and Motter CE, et al. (2014) Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57:2047-2057.
2. Dumas EO, Lawal A, Menon RM, Podsadecki T, Awni W, Dutta S, and Williams L (2011) Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers. J Hepatol 54:S475-S476.
3. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, and Pilot-Matias T, et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594-1603.
4. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, and Nyberg A, et al.; PEARL-III Study; ; PEARL-IV Study (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983-1992.
5. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
6. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, and Sulkowski MS, et al. (2014) Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222-232.
7. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, and Xie W, et al. (2015) In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979-987.
8. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115.
9. Lawitz E, Marbury T, Campbell A, Dumas E, Kapoor M, Pilot-Matias T, Krishnan P, Setze C, Xie W, and Podsadecki T, et al. (2012) Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects. J Hepatol 56:S469-S470.
10. Menon R, Kapoor M, Dumas E, Badri P, Cambell A, Gulati P, Bernstein B, Williams L, Awni W, and Dutta S (2013) Multiple-dose Pharmacokinetics and Safety Following Coadministration of ABT-450/r, ABT-267 and ABT-333 in Caucasian, Japanese and Chinese Subjects (Abstract 1497). Hepatol Int 7: 400.
11. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, and Podsadecki TJ, et al. (2015) Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 63:20-29.
12. Mohd Hanafiah K, Groeger J, Flaxman AD, and Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342.
13. Pawlotsky JM (2004) Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 12:96-102.
14. Polsky-Fisher SL, Vickers S, Cui D, Subramanian R, Arison BH, Agrawal NG, Goel TV, Vessey LK, Murphy MG, and Lasseter KC, et al. (2006) Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers. Drug Metab Dispos 34: 1004-1011.
15. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, and Yoshida EM, et al. (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973-1982.
16. Prakash C, Wang W, O'Connell T, and Johnson KA (2008) CYP2C8- and CYP3A-mediated C-demethylation of (3-[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance. Drug Metab Dispos 36: 2093-2103.
17. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
18. Shah N, Pierce T, and Kowdley KV (2013) Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 22:1107-1121.
19. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
20. Weber C, Gasser R, and Hopfgartner G (1999) Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 27: 810-815.
21. World Health Organization (2011) Hepatitis C. Wkly Epidemiol Rec 86:445-447.
22. Yoo HH, Chung HJ, Lee J, Lee CS, Kang MJ, and Kim DH (2008) Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)-ethanone (LC15-0133) in rat liver microsomes. Drug Metab Dispos 36:485-489.
23. Zeuzem S (2014) Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nat Rev Gastroenterol Hepatol 11:644-645.